{"id": "article-542_0", "title": "New Onset Diabetes After Transplant -- Continuing Education Activity", "content": "New-onset diabetes mellitus after transplantation (NODAT) is the development of diabetes mellitus after solid organ transplantation. NODAT frequently occurs, increasing the risk of infection as well as mortality rates. The appropriate evaluation and management of NODAT by the health care providers result in prompt diagnosis with a subsequent decrease in morbidity and mortality associated with this condition and increases the organ survival after a transplant. This activity describes the pathophysiology, evaluation, and management of NODAT and highlights the role of the interprofessional team in caring for affected patients.", "contents": "New Onset Diabetes After Transplant -- Continuing Education Activity. New-onset diabetes mellitus after transplantation (NODAT) is the development of diabetes mellitus after solid organ transplantation. NODAT frequently occurs, increasing the risk of infection as well as mortality rates. The appropriate evaluation and management of NODAT by the health care providers result in prompt diagnosis with a subsequent decrease in morbidity and mortality associated with this condition and increases the organ survival after a transplant. This activity describes the pathophysiology, evaluation, and management of NODAT and highlights the role of the interprofessional team in caring for affected patients."}
{"id": "article-542_1", "title": "New Onset Diabetes After Transplant -- Continuing Education Activity", "content": "Objectives: Describe the pathophysiology of new-onset diabetes mellitus after organ transplantation. Outline typical laboratory findings for a patient with new-onset diabetes mellitus after organ transplantation. Explain the treatment considerations for patients with new-onset diabetes mellitus after organ transplantation. Review the importance of collaboration and coordination among the interprofessional team to enhance patient care, facilitate treatment planning, and increase patient survival following organ transplantation. Access free multiple choice questions on this topic.", "contents": "New Onset Diabetes After Transplant -- Continuing Education Activity. Objectives: Describe the pathophysiology of new-onset diabetes mellitus after organ transplantation. Outline typical laboratory findings for a patient with new-onset diabetes mellitus after organ transplantation. Explain the treatment considerations for patients with new-onset diabetes mellitus after organ transplantation. Review the importance of collaboration and coordination among the interprofessional team to enhance patient care, facilitate treatment planning, and increase patient survival following organ transplantation. Access free multiple choice questions on this topic."}
{"id": "article-542_2", "title": "New Onset Diabetes After Transplant -- Introduction", "content": "New-onset diabetes mellitus after transplantation (NODAT)\u00a0is\u00a0the occurrence of diabetes mellitus (DM) in a previously non-diabetic person after solid organ transplantation.\u00a0NODAT\u00a0frequently occurs after organ transplantation and increases the risk of infection\u00a0and mortality rates. [1] [2]", "contents": "New Onset Diabetes After Transplant -- Introduction. New-onset diabetes mellitus after transplantation (NODAT)\u00a0is\u00a0the occurrence of diabetes mellitus (DM) in a previously non-diabetic person after solid organ transplantation.\u00a0NODAT\u00a0frequently occurs after organ transplantation and increases the risk of infection\u00a0and mortality rates. [1] [2]"}
{"id": "article-542_3", "title": "New Onset Diabetes After Transplant -- Introduction", "content": "International Consensus Guidelines on NODAT were published in 2003. They recommended that the diagnosis of NODAT should be based on the American Diabetes Association (ADA) criteria for type 2 diabetes. It is\u00a0suggested to the use of modified ADA 2003 criteria to define NODAT and impaired fasting glucose in kidney transplant recipients.", "contents": "New Onset Diabetes After Transplant -- Introduction. International Consensus Guidelines on NODAT were published in 2003. They recommended that the diagnosis of NODAT should be based on the American Diabetes Association (ADA) criteria for type 2 diabetes. It is\u00a0suggested to the use of modified ADA 2003 criteria to define NODAT and impaired fasting glucose in kidney transplant recipients."}
{"id": "article-542_4", "title": "New Onset Diabetes After Transplant -- Etiology", "content": "Patients\u00a0who have\u00a0preexisting risk factors for type 2 DM are more prone to develop NODAT. NODAT risk factors subclassify into two groups of nonmodifiable and\u00a0modifiable risk factors.", "contents": "New Onset Diabetes After Transplant -- Etiology. Patients\u00a0who have\u00a0preexisting risk factors for type 2 DM are more prone to develop NODAT. NODAT risk factors subclassify into two groups of nonmodifiable and\u00a0modifiable risk factors."}
{"id": "article-542_5", "title": "New Onset Diabetes After Transplant -- Etiology -- Age", "content": "Age\u00a0is among the greatest risk factors in the development of\u00a0NODAT. Studies demonstrated that\u00a0the incidence of NODAT is 2.2 times higher in transplant recipients who are more than 45 years of\u00a0age\u00a0compared to younger adults.", "contents": "New Onset Diabetes After Transplant -- Etiology -- Age. Age\u00a0is among the greatest risk factors in the development of\u00a0NODAT. Studies demonstrated that\u00a0the incidence of NODAT is 2.2 times higher in transplant recipients who are more than 45 years of\u00a0age\u00a0compared to younger adults."}
{"id": "article-542_6", "title": "New Onset Diabetes After Transplant -- Etiology -- Ethnicity", "content": "NODAT is more common in the Black and Hispanic population compared to the White population. This difference in the incidence of NODAT can be due to the genetic diversity\u00a0and\u00a0variable effects of immunosuppressive agents on various ethnicities. As an example, tacrolimus has been reported to be a more potent\u00a0cause of\u00a0NODAT in the Black population.", "contents": "New Onset Diabetes After Transplant -- Etiology -- Ethnicity. NODAT is more common in the Black and Hispanic population compared to the White population. This difference in the incidence of NODAT can be due to the genetic diversity\u00a0and\u00a0variable effects of immunosuppressive agents on various ethnicities. As an example, tacrolimus has been reported to be a more potent\u00a0cause of\u00a0NODAT in the Black population."}
{"id": "article-542_7", "title": "New Onset Diabetes After Transplant -- Etiology -- Family History of Diabetes Mellitus and Genetic", "content": "Genetic factors\u00a0are known to be important in NODAT. Based on the evidence, NODAT is more common in people with a history of diabetes in their first-degree relatives. The development of NODAT has genetic links to the alleles of human leukocyte antigen (HLA) A28, A30, B27, and Bw42. The association between single nucleotide polymorphisms (SNPs) and risk for NODAT has been documented in multiple studies. Also, studies show that the association of the R325W polymorphism in the SLC30A8 zinc transporter gene with the R/r inheritance relates to a higher risk of NODAT.\u00a0Other specific gene variants which are associated with NODAT are KCNQ1,\u00a0TCF7L2,\u00a0KCNJ11-Kir6.2, and NFATc4.\u00a0TCF7L2. These variants relate to impaired\u00a0insulin secretion and an\u00a0accelerated rate of gluconeogenesis. Pathogenesis of NODAT in kidney transplant recipients demonstrates a relationship to significant variations of IL-7R, IL-17E, IL-17R, and IL-17RB.", "contents": "New Onset Diabetes After Transplant -- Etiology -- Family History of Diabetes Mellitus and Genetic. Genetic factors\u00a0are known to be important in NODAT. Based on the evidence, NODAT is more common in people with a history of diabetes in their first-degree relatives. The development of NODAT has genetic links to the alleles of human leukocyte antigen (HLA) A28, A30, B27, and Bw42. The association between single nucleotide polymorphisms (SNPs) and risk for NODAT has been documented in multiple studies. Also, studies show that the association of the R325W polymorphism in the SLC30A8 zinc transporter gene with the R/r inheritance relates to a higher risk of NODAT.\u00a0Other specific gene variants which are associated with NODAT are KCNQ1,\u00a0TCF7L2,\u00a0KCNJ11-Kir6.2, and NFATc4.\u00a0TCF7L2. These variants relate to impaired\u00a0insulin secretion and an\u00a0accelerated rate of gluconeogenesis. Pathogenesis of NODAT in kidney transplant recipients demonstrates a relationship to significant variations of IL-7R, IL-17E, IL-17R, and IL-17RB."}
{"id": "article-542_8", "title": "New Onset Diabetes After Transplant -- Etiology -- Pre-diabetes Status", "content": "Abnormal glucose tolerance is another risk factor for NODAT. Patients with pre-diabetic conditions such as fasting blood sugar\u00a0levels between 90 and 100\u00a0mg/dL need to be monitored closely post-transplant and advised on lifestyle modifications to\u00a0avoid weight gain, which on its own can tip the patient\u00a0to develop diabetes mellitus.", "contents": "New Onset Diabetes After Transplant -- Etiology -- Pre-diabetes Status. Abnormal glucose tolerance is another risk factor for NODAT. Patients with pre-diabetic conditions such as fasting blood sugar\u00a0levels between 90 and 100\u00a0mg/dL need to be monitored closely post-transplant and advised on lifestyle modifications to\u00a0avoid weight gain, which on its own can tip the patient\u00a0to develop diabetes mellitus."}
{"id": "article-542_9", "title": "New Onset Diabetes After Transplant -- Etiology -- Obesity", "content": "Obesity confers a significant modifiable risk factor\u00a0for the development of\u00a0NODAT. It\u00a0acts by upregulating of\u00a0inflammatory markers and C-reactive protein levels. Adipose tissue increases the production of\u00a0tumor necrosis factor-alpha (TNF-alpha), which causes defects in the phosphorylation of the glucose receptor and decreases the expression of insulin-sensitive glucose transporters. This mechanism\u00a0leads to insulin resistance and DM. Furthermore, adipose tissue induces\u00a0IL-6 synthesis, which is associated with glucose intolerance. Increasing\u00a0in adipose tissue results in the reduction of adiponectin, a hormone that reduces\u00a0the risk of DM. In\u00a0transplant recipients, the level of\u00a0adiponectin is low before transplant, which in turn is a risk factor to develop NODAT.", "contents": "New Onset Diabetes After Transplant -- Etiology -- Obesity. Obesity confers a significant modifiable risk factor\u00a0for the development of\u00a0NODAT. It\u00a0acts by upregulating of\u00a0inflammatory markers and C-reactive protein levels. Adipose tissue increases the production of\u00a0tumor necrosis factor-alpha (TNF-alpha), which causes defects in the phosphorylation of the glucose receptor and decreases the expression of insulin-sensitive glucose transporters. This mechanism\u00a0leads to insulin resistance and DM. Furthermore, adipose tissue induces\u00a0IL-6 synthesis, which is associated with glucose intolerance. Increasing\u00a0in adipose tissue results in the reduction of adiponectin, a hormone that reduces\u00a0the risk of DM. In\u00a0transplant recipients, the level of\u00a0adiponectin is low before transplant, which in turn is a risk factor to develop NODAT."}
{"id": "article-542_10", "title": "New Onset Diabetes After Transplant -- Etiology -- Post-transplant Medications", "content": "Corticosteroids\u00a0are\u00a0traditionally associated with hyperglycemia and DM by decreasing peripheral insulin sensitivity, inhibiting pancreatic insulin production and secretion, increasing hepatic gluconeogenesis, and promoting\u00a0protein degradation to free amino acids in muscles. The diabetogenic effect of corticosteroids in developing NODAT has been suggested to be related to both the dosage and the duration of therapy. In general, post-transplant steroid therapy increases the risk of NODAT by 42%. While a steroid-free regimen reduces\u00a0the\u00a0NODAT risk, glucose tolerance can significantly improve by reducing the\u00a0daily dose of prednisone to 5 mg or lower\u00a0post-transplantation. Using a higher dosage of\u00a0prednisolone, such as 0.01 mg/kg/day, will increase the risk of NODAT by 5%.\u00a0Calcineurin inhibitors (CNI)\u00a0are given to most transplant recipients and\u00a0are associated with hyperglycemia. CNI reduces the number of\u00a0glucose transporter type 4 (GLUT-4) receptor molecules\u00a0on the adipocytes. GLUT-4\u00a0is an insulin-regulated protein, and its task is to\u00a0transport the glucose into adipocytes and\u00a0striated muscle cells. A decrease\u00a0in the number of GLUT-4 receptors leads to a reduction of\u00a0glucose uptake by these cells, which resultant hyperglycemia. Also, CNIs decrease the pancreatic beta-cell density\u00a0by interfering with the activated T-cell signaling in pancreatic beta-cells. As a result, this pathway\u00a0activates the mutated genes responsible for DM and leads to\u00a0reduced insulin synthesis.\u00a0Studies report that the incidence of NODAT is significantly higher in\u00a0patients\u00a0who got treatment with tacrolimus compared to those who\u00a0have had therapy with cyclosporine. Tacrolimus\u00a0acts by inhibiting T-cell activity, which results in inhibition of\u00a0interleukin-2 synthesis, and leads to a failure of T-cell production. Beyond the mechanism mentioned above, tacrolimus also causes hyperglycemia by reducing\u00a0glucokinase activity in pancreatic islets leading to suppression of\u00a0glucose-induced insulin release. The effect of tacrolimus in the development of\u00a0glucose intolerance is reversible\u00a0with drug discontinuation. Sirolimus is another immunosuppressant that has been associated with NODAT, especially when used in combination with CNI. There is no known recognized association between mycophenolate mofetil and azathioprine use and the development of NODAT.", "contents": "New Onset Diabetes After Transplant -- Etiology -- Post-transplant Medications. Corticosteroids\u00a0are\u00a0traditionally associated with hyperglycemia and DM by decreasing peripheral insulin sensitivity, inhibiting pancreatic insulin production and secretion, increasing hepatic gluconeogenesis, and promoting\u00a0protein degradation to free amino acids in muscles. The diabetogenic effect of corticosteroids in developing NODAT has been suggested to be related to both the dosage and the duration of therapy. In general, post-transplant steroid therapy increases the risk of NODAT by 42%. While a steroid-free regimen reduces\u00a0the\u00a0NODAT risk, glucose tolerance can significantly improve by reducing the\u00a0daily dose of prednisone to 5 mg or lower\u00a0post-transplantation. Using a higher dosage of\u00a0prednisolone, such as 0.01 mg/kg/day, will increase the risk of NODAT by 5%.\u00a0Calcineurin inhibitors (CNI)\u00a0are given to most transplant recipients and\u00a0are associated with hyperglycemia. CNI reduces the number of\u00a0glucose transporter type 4 (GLUT-4) receptor molecules\u00a0on the adipocytes. GLUT-4\u00a0is an insulin-regulated protein, and its task is to\u00a0transport the glucose into adipocytes and\u00a0striated muscle cells. A decrease\u00a0in the number of GLUT-4 receptors leads to a reduction of\u00a0glucose uptake by these cells, which resultant hyperglycemia. Also, CNIs decrease the pancreatic beta-cell density\u00a0by interfering with the activated T-cell signaling in pancreatic beta-cells. As a result, this pathway\u00a0activates the mutated genes responsible for DM and leads to\u00a0reduced insulin synthesis.\u00a0Studies report that the incidence of NODAT is significantly higher in\u00a0patients\u00a0who got treatment with tacrolimus compared to those who\u00a0have had therapy with cyclosporine. Tacrolimus\u00a0acts by inhibiting T-cell activity, which results in inhibition of\u00a0interleukin-2 synthesis, and leads to a failure of T-cell production. Beyond the mechanism mentioned above, tacrolimus also causes hyperglycemia by reducing\u00a0glucokinase activity in pancreatic islets leading to suppression of\u00a0glucose-induced insulin release. The effect of tacrolimus in the development of\u00a0glucose intolerance is reversible\u00a0with drug discontinuation. Sirolimus is another immunosuppressant that has been associated with NODAT, especially when used in combination with CNI. There is no known recognized association between mycophenolate mofetil and azathioprine use and the development of NODAT."}
{"id": "article-542_11", "title": "New Onset Diabetes After Transplant -- Etiology -- Hypomagnesemia", "content": "Hypomagnesemia after transplant is another risk factor for NODAT. CNIs can induce hypomagnesemia by inhibition of the renal magnesium transporter, resulting in\u00a0renal magnesium wasting.", "contents": "New Onset Diabetes After Transplant -- Etiology -- Hypomagnesemia. Hypomagnesemia after transplant is another risk factor for NODAT. CNIs can induce hypomagnesemia by inhibition of the renal magnesium transporter, resulting in\u00a0renal magnesium wasting."}
{"id": "article-542_12", "title": "New Onset Diabetes After Transplant -- Etiology -- Viral Infections", "content": "Infection and inflammation are two other factors that contribute to glucose intolerance and the development of DM.\u00a0HCV infection has a diabetogenic effect\u00a0by causing insulin resistance and decreasing hepatic glucose uptake and glycogenesis. Also, HCV has a cytopathic effect on pancreatic beta cells. Studies show that the incidence of NODAT\u00a0is 25.6% in those who are HCV-positive, while it is 14.4% in those with no HCV infection. [3] [4] [5] [6] [7] [8] Antiviral therapy has been a recommended approach before transplant, but it is still unclear\u00a0whether the response to therapy\u00a0can\u00a0improve glycemic control. Using tacrolimus in patients with HCV\u00a0aggravates the risk of\u00a0NODAT. Active cytomegalovirus (CMV) infection decreases insulin\u00a0secretion by\u00a0impairing the pancreatic beta cells. CMV can induce the release of cytokines, which leads to apoptosis and mal-functioning of pancreatic beta-cells. As a result, CMV can predispose the patients to NODAT. [9] [10] [11] [12]", "contents": "New Onset Diabetes After Transplant -- Etiology -- Viral Infections. Infection and inflammation are two other factors that contribute to glucose intolerance and the development of DM.\u00a0HCV infection has a diabetogenic effect\u00a0by causing insulin resistance and decreasing hepatic glucose uptake and glycogenesis. Also, HCV has a cytopathic effect on pancreatic beta cells. Studies show that the incidence of NODAT\u00a0is 25.6% in those who are HCV-positive, while it is 14.4% in those with no HCV infection. [3] [4] [5] [6] [7] [8] Antiviral therapy has been a recommended approach before transplant, but it is still unclear\u00a0whether the response to therapy\u00a0can\u00a0improve glycemic control. Using tacrolimus in patients with HCV\u00a0aggravates the risk of\u00a0NODAT. Active cytomegalovirus (CMV) infection decreases insulin\u00a0secretion by\u00a0impairing the pancreatic beta cells. CMV can induce the release of cytokines, which leads to apoptosis and mal-functioning of pancreatic beta-cells. As a result, CMV can predispose the patients to NODAT. [9] [10] [11] [12]"}
{"id": "article-542_13", "title": "New Onset Diabetes After Transplant -- Epidemiology", "content": "NODAT is\u00a0more common in Black and Hispanic patients compared to Whites, which\u00a0might be because of\u00a0genetic polymorphisms among Black and Hispanic transplant recipients. NODAT incidence in the United States has been reported to be about 9.1% of patients at 3 months, 16% at 12 months, and 24% at 36 months post-transplantation. Also, NODAT has been estimated to\u00a0occur in about\u00a04 to 25% of renal transplants, 2.5 to 25% of\u00a0liver transplants, 4 to 40% of\u00a0heart transplants, and 30 to 35% of\u00a0lung transplant recipients. The risk of NODAT increases in liver transplants if the patient\u00a0has\u00a0an HCV infection and can range between 40% and 60% . Some studies\u00a0report the range of NODAT to be from 7 to 30% in the first year after kidney transplantation. Also, the majority of organ recipients (about 76.5%) develop NODAT in the first 3 months. After 6 months, the incidence of DM is almost the same as the patients with no transplant. Using higher doses of\u00a0immunosuppressive medications after\u00a0transplant correlates with a higher incidence of NODAT. [13] [14] [15]", "contents": "New Onset Diabetes After Transplant -- Epidemiology. NODAT is\u00a0more common in Black and Hispanic patients compared to Whites, which\u00a0might be because of\u00a0genetic polymorphisms among Black and Hispanic transplant recipients. NODAT incidence in the United States has been reported to be about 9.1% of patients at 3 months, 16% at 12 months, and 24% at 36 months post-transplantation. Also, NODAT has been estimated to\u00a0occur in about\u00a04 to 25% of renal transplants, 2.5 to 25% of\u00a0liver transplants, 4 to 40% of\u00a0heart transplants, and 30 to 35% of\u00a0lung transplant recipients. The risk of NODAT increases in liver transplants if the patient\u00a0has\u00a0an HCV infection and can range between 40% and 60% . Some studies\u00a0report the range of NODAT to be from 7 to 30% in the first year after kidney transplantation. Also, the majority of organ recipients (about 76.5%) develop NODAT in the first 3 months. After 6 months, the incidence of DM is almost the same as the patients with no transplant. Using higher doses of\u00a0immunosuppressive medications after\u00a0transplant correlates with a higher incidence of NODAT. [13] [14] [15]"}
{"id": "article-542_14", "title": "New Onset Diabetes After Transplant -- Pathophysiology", "content": "The pathophysiology of NODAT is almost as same as type 2 DM: increase in\u00a0insulin resistance and decrease in insulin secretion. In\u00a0NODAT, insulin hyposecretion seems to have a more important role in glucose intolerance. NODAT more likely occurs in patients who have other risk factors in developing DM type 2. Immunosuppression regimen is one of the leading causes of NODAT; this\u00a0acts by affecting insulin secretion and action. [16]", "contents": "New Onset Diabetes After Transplant -- Pathophysiology. The pathophysiology of NODAT is almost as same as type 2 DM: increase in\u00a0insulin resistance and decrease in insulin secretion. In\u00a0NODAT, insulin hyposecretion seems to have a more important role in glucose intolerance. NODAT more likely occurs in patients who have other risk factors in developing DM type 2. Immunosuppression regimen is one of the leading causes of NODAT; this\u00a0acts by affecting insulin secretion and action. [16]"}
{"id": "article-542_15", "title": "New Onset Diabetes After Transplant -- History and Physical", "content": "As with DM, most patients with\u00a0NODAT are asymptomatic. The detection of many patients will be due to inpatient glucose monitoring and hyperglycemia on laboratory tests after\u00a0transplant surgery. Hence, glucose testing is in the recommendations for post-transplant screening in all transplant patients; this can result in early detection of NODAT. Symptoms\u00a0are the same as in non-transplant DM patients and include\u00a0polyuria, polydipsia, polyphagia, weight loss, blurry vision, neuropathy, numbness of extremities, and symptoms of infection.\u00a0 The physical\u00a0exam includes vital signs, the extent of hydration, funduscopic eye exam, vascular and neurologic examinations, and a foot assessment. The physical examination findings\u00a0might be unrevealing, although observable end-organ damage may occur.", "contents": "New Onset Diabetes After Transplant -- History and Physical. As with DM, most patients with\u00a0NODAT are asymptomatic. The detection of many patients will be due to inpatient glucose monitoring and hyperglycemia on laboratory tests after\u00a0transplant surgery. Hence, glucose testing is in the recommendations for post-transplant screening in all transplant patients; this can result in early detection of NODAT. Symptoms\u00a0are the same as in non-transplant DM patients and include\u00a0polyuria, polydipsia, polyphagia, weight loss, blurry vision, neuropathy, numbness of extremities, and symptoms of infection.\u00a0 The physical\u00a0exam includes vital signs, the extent of hydration, funduscopic eye exam, vascular and neurologic examinations, and a foot assessment. The physical examination findings\u00a0might be unrevealing, although observable end-organ damage may occur."}
{"id": "article-542_16", "title": "New Onset Diabetes After Transplant -- Evaluation", "content": "NODAT is predictable by\u00a0evaluation of\u00a0the risk factors such as pre-diabetic status and obesity.\u00a0Some studies suggest that assessment of\u00a0preoperative insulin resistance, insulin sensitivity, and beta-cell function (c-peptide levels) may be helpful to predict NODAT but remains unconfirmed by other studies. Guidelines that define the criteria for the diagnosis of NODAT are\u00a0identical to the diagnostic criteria in DM: Symptoms of diabetes and random plasma glucose greater than or equal to 200 mg/dL (11.1 mmol/L) Fasting plasma glucose greater than or equal to 126 mg/dL (7.0 mmol/L) which requires repetition on another day Two-hour plasma glucose greater than or equal to 200 mg/dL (11.1 mmol/L) during an oral glucose tolerance test (OGTT)", "contents": "New Onset Diabetes After Transplant -- Evaluation. NODAT is predictable by\u00a0evaluation of\u00a0the risk factors such as pre-diabetic status and obesity.\u00a0Some studies suggest that assessment of\u00a0preoperative insulin resistance, insulin sensitivity, and beta-cell function (c-peptide levels) may be helpful to predict NODAT but remains unconfirmed by other studies. Guidelines that define the criteria for the diagnosis of NODAT are\u00a0identical to the diagnostic criteria in DM: Symptoms of diabetes and random plasma glucose greater than or equal to 200 mg/dL (11.1 mmol/L) Fasting plasma glucose greater than or equal to 126 mg/dL (7.0 mmol/L) which requires repetition on another day Two-hour plasma glucose greater than or equal to 200 mg/dL (11.1 mmol/L) during an oral glucose tolerance test (OGTT)"}
{"id": "article-542_17", "title": "New Onset Diabetes After Transplant -- Evaluation", "content": "OGTT\u00a0is the gold standard for NODAT diagnosis, especially in the\u00a0early stages of transplantation. Because of the reduction of red blood cell survival after transplant, the diagnosis of NODAT based on HbA1c is not accurate in the first 3 months after the transplantation and is therefore not recommended. Beyond 3 months, the new hemoglobin\u00a0would be\u00a0synthesized and glycated for the appropriate period, and HbA1c greater than or equal to 6.5 percent\u00a0can be utilized to diagnose NODAT. Even many studies don't recommend HbA1c alone\u00a0as a screening tool for NODAT\u00a0in the first year after transplant. [3] [17] [18] [12] [19] Although hemoglobin A1c can be used is some patients to diagnose diabetes mellitus, in the setting of ESRD, RBC turnover makes this unreliable.", "contents": "New Onset Diabetes After Transplant -- Evaluation. OGTT\u00a0is the gold standard for NODAT diagnosis, especially in the\u00a0early stages of transplantation. Because of the reduction of red blood cell survival after transplant, the diagnosis of NODAT based on HbA1c is not accurate in the first 3 months after the transplantation and is therefore not recommended. Beyond 3 months, the new hemoglobin\u00a0would be\u00a0synthesized and glycated for the appropriate period, and HbA1c greater than or equal to 6.5 percent\u00a0can be utilized to diagnose NODAT. Even many studies don't recommend HbA1c alone\u00a0as a screening tool for NODAT\u00a0in the first year after transplant. [3] [17] [18] [12] [19] Although hemoglobin A1c can be used is some patients to diagnose diabetes mellitus, in the setting of ESRD, RBC turnover makes this unreliable."}
{"id": "article-542_18", "title": "New Onset Diabetes After Transplant -- Evaluation", "content": "Early detection of NODAT is helpful\u00a0as it\u00a0reduces the risk\u00a0and complications of DM. The recommendation is for post-transplantation screening for NODAT in all patients undergoing solid organ transplants. Transplantation centers perform the screening tests weekly in the first month and continue screening at months 3, 6, and 12 post-transplantation. After the first year, the risk of NODAT is lower, and the recommendation is for yearly screening. [8]", "contents": "New Onset Diabetes After Transplant -- Evaluation. Early detection of NODAT is helpful\u00a0as it\u00a0reduces the risk\u00a0and complications of DM. The recommendation is for post-transplantation screening for NODAT in all patients undergoing solid organ transplants. Transplantation centers perform the screening tests weekly in the first month and continue screening at months 3, 6, and 12 post-transplantation. After the first year, the risk of NODAT is lower, and the recommendation is for yearly screening. [8]"}
{"id": "article-542_19", "title": "New Onset Diabetes After Transplant -- Treatment / Management", "content": "Some of the factors that induce post-transplant hyperglycemia\u00a0are postoperative surgical stress, pain, and high doses of immunosuppressants.\u00a0Early detection of hyperglycemia is crucial because early optimization of inpatient plasma glucose\u00a0has\u00a0a beneficial effect on the long-term patient and graft survival. The goal for management\u00a0is adequate glycemic control to minimize hyperglycemia complications. The first steps for glycemic control should focus on non-pharmacological\u00a0factors that elevate blood glucose. These steps include\u00a0switching from more diabetogenic immunosuppressants to the less diabetogenic ones or alter the dose of the immunosuppressants with the view of optimizing glycemic control, e.g.,\u00a0reducing corticosteroid\u00a0dose. Sometimes by simply tapering the corticosteroids soon after transplant can control without medical therapy.", "contents": "New Onset Diabetes After Transplant -- Treatment / Management. Some of the factors that induce post-transplant hyperglycemia\u00a0are postoperative surgical stress, pain, and high doses of immunosuppressants.\u00a0Early detection of hyperglycemia is crucial because early optimization of inpatient plasma glucose\u00a0has\u00a0a beneficial effect on the long-term patient and graft survival. The goal for management\u00a0is adequate glycemic control to minimize hyperglycemia complications. The first steps for glycemic control should focus on non-pharmacological\u00a0factors that elevate blood glucose. These steps include\u00a0switching from more diabetogenic immunosuppressants to the less diabetogenic ones or alter the dose of the immunosuppressants with the view of optimizing glycemic control, e.g.,\u00a0reducing corticosteroid\u00a0dose. Sometimes by simply tapering the corticosteroids soon after transplant can control without medical therapy."}
{"id": "article-542_20", "title": "New Onset Diabetes After Transplant -- Treatment / Management", "content": "However, clinicians should be thoughtful about the possibility of acute rejection.\u00a0If lifestyle modification and immunosuppressants adjustment are insufficient to control hyperglycemia, then pharmacotherapy should be initiated.\u00a0Significant numbers of\u00a0the patients require insulin therapy to manage postoperative hyperglycemia while in the hospital. In hospitalized patients, as a result of frequent changes in immunosuppressants doses and\u00a0varying nutritional intake, fluctuations of blood glucose levels are common. Intravenous (IV) insulin is a good initial\u00a0choice since it is easily titratable, which results in tight plasma glucose control and is safe, particularly post-transplant when graft function is\u00a0still unstable. Choosing between insulin and oral hypoglycemic agents depends on the severity of hyperglycemia. Based on the\u00a0IV insulin infusion requirement, subcutaneous insulin doses can be calculated after proper glycemic control or discharge. Oral hypoglycemic therapy at the time of discharge is an option in patients who\u00a0required low-dose insulin therapy in the inpatient setting. There are no known drug-drug interactions between immunosuppressants and oral antidiabetic agents.", "contents": "New Onset Diabetes After Transplant -- Treatment / Management. However, clinicians should be thoughtful about the possibility of acute rejection.\u00a0If lifestyle modification and immunosuppressants adjustment are insufficient to control hyperglycemia, then pharmacotherapy should be initiated.\u00a0Significant numbers of\u00a0the patients require insulin therapy to manage postoperative hyperglycemia while in the hospital. In hospitalized patients, as a result of frequent changes in immunosuppressants doses and\u00a0varying nutritional intake, fluctuations of blood glucose levels are common. Intravenous (IV) insulin is a good initial\u00a0choice since it is easily titratable, which results in tight plasma glucose control and is safe, particularly post-transplant when graft function is\u00a0still unstable. Choosing between insulin and oral hypoglycemic agents depends on the severity of hyperglycemia. Based on the\u00a0IV insulin infusion requirement, subcutaneous insulin doses can be calculated after proper glycemic control or discharge. Oral hypoglycemic therapy at the time of discharge is an option in patients who\u00a0required low-dose insulin therapy in the inpatient setting. There are no known drug-drug interactions between immunosuppressants and oral antidiabetic agents."}
{"id": "article-542_21", "title": "New Onset Diabetes After Transplant -- Treatment / Management", "content": "Metformin is one of the more popular agents which improves insulin sensitivity. Often the glomerular filtration rate\u00a0increases\u00a0adequately with\u00a0well-functioning grafts so it can be used safely for most patients and is\u00a0the first-line oral agent in NODAT management.\u00a0Sulfonylureas enhance insulin secretion and are used in NODAT extensively. Their side effects can be post-transplant weight gain and hypoglycemia. Thiazolidinediones are selective agonists of the peroxisomal proliferator-activated receptor gamma and improve glucose tolerance and insulin sensitivity in NODAT. Thiazolidinediones are contraindicated in congestive heart failure and should be used with caution if there is graft malfunction. Repaglinide is a safe drug among the meglitinides and acts by inducing insulin secretion. Dipeptidyl peptidase-4 (DPP-4) antagonists\u00a0act by inhibiting the degradation of glucagon-like peptide 1, which results in\u00a0pancreatic insulin secretion. Among the DPP-4 antagonists, sitagliptin is a good choice in NODAT. Using incretin-based therapy such as vildagliptin and\u00a0sitagliptin needs to be avoided in liver impairment and renal insufficiency; their safety in NODAT is still under study.", "contents": "New Onset Diabetes After Transplant -- Treatment / Management. Metformin is one of the more popular agents which improves insulin sensitivity. Often the glomerular filtration rate\u00a0increases\u00a0adequately with\u00a0well-functioning grafts so it can be used safely for most patients and is\u00a0the first-line oral agent in NODAT management.\u00a0Sulfonylureas enhance insulin secretion and are used in NODAT extensively. Their side effects can be post-transplant weight gain and hypoglycemia. Thiazolidinediones are selective agonists of the peroxisomal proliferator-activated receptor gamma and improve glucose tolerance and insulin sensitivity in NODAT. Thiazolidinediones are contraindicated in congestive heart failure and should be used with caution if there is graft malfunction. Repaglinide is a safe drug among the meglitinides and acts by inducing insulin secretion. Dipeptidyl peptidase-4 (DPP-4) antagonists\u00a0act by inhibiting the degradation of glucagon-like peptide 1, which results in\u00a0pancreatic insulin secretion. Among the DPP-4 antagonists, sitagliptin is a good choice in NODAT. Using incretin-based therapy such as vildagliptin and\u00a0sitagliptin needs to be avoided in liver impairment and renal insufficiency; their safety in NODAT is still under study."}
{"id": "article-542_22", "title": "New Onset Diabetes After Transplant -- Treatment / Management", "content": "Because patients with\u00a0transplants are at increased risk of\u00a0hypoglycemia\u00a0and frequently have a concurrent history of heart disease, guidelines recommend an HbA1c goal of 7 to 7.5% in these patients. Studies demonstrated that in patients with hypertension and\u00a0congestive heart failure, using\u00a0ACEIs or ARBs has a significant role in\u00a0reducing the incidence of NODAT. Treatment of infections such as HCV should be a consideration before transplant. [20] [18] [8] [7] [12]", "contents": "New Onset Diabetes After Transplant -- Treatment / Management. Because patients with\u00a0transplants are at increased risk of\u00a0hypoglycemia\u00a0and frequently have a concurrent history of heart disease, guidelines recommend an HbA1c goal of 7 to 7.5% in these patients. Studies demonstrated that in patients with hypertension and\u00a0congestive heart failure, using\u00a0ACEIs or ARBs has a significant role in\u00a0reducing the incidence of NODAT. Treatment of infections such as HCV should be a consideration before transplant. [20] [18] [8] [7] [12]"}
{"id": "article-542_23", "title": "New Onset Diabetes After Transplant -- Differential Diagnosis", "content": "Diabetes mellitus Stress hyperglycemia", "contents": "New Onset Diabetes After Transplant -- Differential Diagnosis. Diabetes mellitus Stress hyperglycemia"}
{"id": "article-542_24", "title": "New Onset Diabetes After Transplant -- Prognosis", "content": "NODAT outcome is affected by different factors, including the type of organ transplant, age, obesity, other cardiovascular risk factors, and immunosuppressants. Studies show a higher mortality rate in patients with NODAT\u00a0compared to those with type 2 DM. NODAT decreases patient survival by increasing both cardiovascular events and\u00a0the risk of infections.\u00a0NODAT is associated with a higher prevalence\u00a0of rejection and post-transplant renal failure. Studies showed that graft survival in patients with NODAT was 48%, while it was 70% in a patient without NODAT. Also, studies demonstrate that in kidney transplant recipients, cardiovascular events are 2 to 3 fold more in NODAT in comparison with other patients. Additionally, diabetic microvascular complications develop rapidly\u00a0in patients with NODAT than traditional DM. [21] [22] [18]", "contents": "New Onset Diabetes After Transplant -- Prognosis. NODAT outcome is affected by different factors, including the type of organ transplant, age, obesity, other cardiovascular risk factors, and immunosuppressants. Studies show a higher mortality rate in patients with NODAT\u00a0compared to those with type 2 DM. NODAT decreases patient survival by increasing both cardiovascular events and\u00a0the risk of infections.\u00a0NODAT is associated with a higher prevalence\u00a0of rejection and post-transplant renal failure. Studies showed that graft survival in patients with NODAT was 48%, while it was 70% in a patient without NODAT. Also, studies demonstrate that in kidney transplant recipients, cardiovascular events are 2 to 3 fold more in NODAT in comparison with other patients. Additionally, diabetic microvascular complications develop rapidly\u00a0in patients with NODAT than traditional DM. [21] [22] [18]"}
{"id": "article-542_25", "title": "New Onset Diabetes After Transplant -- Complications", "content": "NODAT can cause similar complications to traditional DM, including neuropathy,\u00a0ophthalmopathy,\u00a0nephropathy, ketoacidosis, and\u00a0episodes of hypoglycemia. Even though these manifestations are similar to DM, the rate at which they occur is remarkably accelerated. Other than the increased risk of transplant rejection, there is a higher incidence of infection and late cardiovascular events, which leads to a higher mortality rate. [16] [2] [13]", "contents": "New Onset Diabetes After Transplant -- Complications. NODAT can cause similar complications to traditional DM, including neuropathy,\u00a0ophthalmopathy,\u00a0nephropathy, ketoacidosis, and\u00a0episodes of hypoglycemia. Even though these manifestations are similar to DM, the rate at which they occur is remarkably accelerated. Other than the increased risk of transplant rejection, there is a higher incidence of infection and late cardiovascular events, which leads to a higher mortality rate. [16] [2] [13]"}
{"id": "article-542_26", "title": "New Onset Diabetes After Transplant -- Consultations", "content": "Endocrinologists Ophthalmologists Podiatrists Cardiologists Nephrologists Dietitians Diabetic nurse educator", "contents": "New Onset Diabetes After Transplant -- Consultations. Endocrinologists Ophthalmologists Podiatrists Cardiologists Nephrologists Dietitians Diabetic nurse educator"}
{"id": "article-542_27", "title": "New Onset Diabetes After Transplant -- Deterrence and Patient Education", "content": "NODAT management\u00a0should ideally start before the organ transplant. Pre-transplant patients should receive counseling regarding the risk factors of developing NODAT and the ways to prevent it. Attention to\u00a0avoid weight gain\u00a0is an established step\u00a0to prevent NODAT. Weight loss can prevent NODAT in overweight patients with prediabetic status. In high-risk groups such as obese patients,\u00a0the goal\u00a0should include weight loss with diet and\u00a0increasing physical activity with target weight loss of 5% to 10% of total body weight and following up with the dietitian before and after transplant. Patients should be advised to eat a healthy, low-calorie, and low-fat diet. Weight loss immediately after transplant is not recommended, as it will delay\u00a0wound healing.", "contents": "New Onset Diabetes After Transplant -- Deterrence and Patient Education. NODAT management\u00a0should ideally start before the organ transplant. Pre-transplant patients should receive counseling regarding the risk factors of developing NODAT and the ways to prevent it. Attention to\u00a0avoid weight gain\u00a0is an established step\u00a0to prevent NODAT. Weight loss can prevent NODAT in overweight patients with prediabetic status. In high-risk groups such as obese patients,\u00a0the goal\u00a0should include weight loss with diet and\u00a0increasing physical activity with target weight loss of 5% to 10% of total body weight and following up with the dietitian before and after transplant. Patients should be advised to eat a healthy, low-calorie, and low-fat diet. Weight loss immediately after transplant is not recommended, as it will delay\u00a0wound healing."}
{"id": "article-542_28", "title": "New Onset Diabetes After Transplant -- Deterrence and Patient Education", "content": "After being diagnosed with NODAT, as with DM, self-glucose monitoring and compliance with treatment are essential. Also, patients\u00a0should be aware of the importance of an annual eye exam, which is even more important than in traditional diabetes patients. NODAT patients are prone to\u00a0have an acceleration of cataracts due to the universal use of both corticosteroids and immunosuppressants. Foot exams should be part of every clinical visit.\u00a0Immunosuppressants place NODAT patients at increased risk of different infections, so\u00a0compliance with annual influenza and\u00a0pneumococcal vaccines\u00a0is critical\u00a0in this population. Those patients who desire to get pregnant should be encouraged to wait\u00a0at least 1 year after the transplantation to decrease the risk of rejection. The transplant team should be involved in all stages before, during, and after pregnancy to reduce\u00a0the comorbidities of\u00a0both mother and baby. [3] [18]", "contents": "New Onset Diabetes After Transplant -- Deterrence and Patient Education. After being diagnosed with NODAT, as with DM, self-glucose monitoring and compliance with treatment are essential. Also, patients\u00a0should be aware of the importance of an annual eye exam, which is even more important than in traditional diabetes patients. NODAT patients are prone to\u00a0have an acceleration of cataracts due to the universal use of both corticosteroids and immunosuppressants. Foot exams should be part of every clinical visit.\u00a0Immunosuppressants place NODAT patients at increased risk of different infections, so\u00a0compliance with annual influenza and\u00a0pneumococcal vaccines\u00a0is critical\u00a0in this population. Those patients who desire to get pregnant should be encouraged to wait\u00a0at least 1 year after the transplantation to decrease the risk of rejection. The transplant team should be involved in all stages before, during, and after pregnancy to reduce\u00a0the comorbidities of\u00a0both mother and baby. [3] [18]"}
{"id": "article-542_29", "title": "New Onset Diabetes After Transplant -- Enhancing Healthcare Team Outcomes", "content": "Coordination of care among all\u00a0team members, including nurses, internists, nutritionists, surgeons, endocrinologists, nephrologists and, infectious disease specialists, is an essential factor in the management of\u00a0pre-existing diabetes or NODAT in transplant patients. Adequate blood glucose control, as well as treatment of comorbidities, is the backbone\u00a0in the management of NODAT as it increases patient survival and decreases the risk of graft rejection. Selecting the right immunosuppressants with the appropriate dose is one of the steps to prevent NODAT, but the risk of developing diabetes after transplantation should be weighed against the risk of transplant rejection.\u00a0At the time of discharge, each caring team's responsibility is to explain the above\u00a0to the patient. Also, education coordination by the nurses and clinicians of the patient and the family about the medical therapies and their side effects is critical as it can impact the patient survival. [3] [7] [Level 1]", "contents": "New Onset Diabetes After Transplant -- Enhancing Healthcare Team Outcomes. Coordination of care among all\u00a0team members, including nurses, internists, nutritionists, surgeons, endocrinologists, nephrologists and, infectious disease specialists, is an essential factor in the management of\u00a0pre-existing diabetes or NODAT in transplant patients. Adequate blood glucose control, as well as treatment of comorbidities, is the backbone\u00a0in the management of NODAT as it increases patient survival and decreases the risk of graft rejection. Selecting the right immunosuppressants with the appropriate dose is one of the steps to prevent NODAT, but the risk of developing diabetes after transplantation should be weighed against the risk of transplant rejection.\u00a0At the time of discharge, each caring team's responsibility is to explain the above\u00a0to the patient. Also, education coordination by the nurses and clinicians of the patient and the family about the medical therapies and their side effects is critical as it can impact the patient survival. [3] [7] [Level 1]"}
{"id": "article-542_30", "title": "New Onset Diabetes After Transplant -- Enhancing Healthcare Team Outcomes", "content": "Diagnosis and management of NODAT require an interprofessional team approach, including physicians, specialists, specialty-trained nurses, and pharmacists, all collaborating across disciplines to achieve optimal patient results. Clinicians (MDs, DOs, NPs, PAs) will typically be the ones to diagnose the condition and order the lab tests. They will also place the initial orders for therapeutic management, which nursing will administer. Nursing will also be responsible for monitoring patient response and serum glucose, documenting and reporting back to the prescribing clinician. Pharmacists can make medication recommendations based on the patient's current drug profile, comorbid conditions, verify dosing, and report recommendations to the nurses or prescribers. [Level 5]", "contents": "New Onset Diabetes After Transplant -- Enhancing Healthcare Team Outcomes. Diagnosis and management of NODAT require an interprofessional team approach, including physicians, specialists, specialty-trained nurses, and pharmacists, all collaborating across disciplines to achieve optimal patient results. Clinicians (MDs, DOs, NPs, PAs) will typically be the ones to diagnose the condition and order the lab tests. They will also place the initial orders for therapeutic management, which nursing will administer. Nursing will also be responsible for monitoring patient response and serum glucose, documenting and reporting back to the prescribing clinician. Pharmacists can make medication recommendations based on the patient's current drug profile, comorbid conditions, verify dosing, and report recommendations to the nurses or prescribers. [Level 5]"}
{"id": "article-542_31", "title": "New Onset Diabetes After Transplant -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "New Onset Diabetes After Transplant -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}